AMEA
As a professional service, Guardant360 CDx reports mutations
in 74 genes.1,2*
Detect guideline-recommended biomarkers across
all 4 major alteration classes.1
*This report has not been approved by the FDA.
†For these genes, alterations reported may include germline (inherited) alterations but not somatic (not inherited) alterations. The assay filters germline variants from reporting except for pathogenic BRCA1, BRCA2, ATM, and CDK12 alterations. However, if a reported alteration is suspected to be germline, confirmatory testing should be considered in the appropriate clinical context. The test is not intended to replace germline testing or to provide information about cancer predisposition.
‡For these genes, alterations reported may include somatic (not inherited) alterations or germline (inherited) alterations. The assay filters germline variants from reporting except for pathogenic BRCA1, BRCA2, ATM, and CDK12 alterations. However, if a reported alteration is suspected to be germline, confirmatory testing should be considered in the appropriate clinical context. The test is not intended to replace germline testing or to provide information about cancer predisposition.
Adapted from the Guardant360® CDx Technical Information.